LT2010104A - Single stranded recombinant antibody fragment able to neutralize cytolytic activity of vaginolysin - Google Patents

Single stranded recombinant antibody fragment able to neutralize cytolytic activity of vaginolysin

Info

Publication number
LT2010104A
LT2010104A LT2010104A LT2010104A LT2010104A LT 2010104 A LT2010104 A LT 2010104A LT 2010104 A LT2010104 A LT 2010104A LT 2010104 A LT2010104 A LT 2010104A LT 2010104 A LT2010104 A LT 2010104A
Authority
LT
Lithuania
Prior art keywords
antibody fragment
recombinant antibody
single stranded
cytolytic activity
vaginolysin
Prior art date
Application number
LT2010104A
Other languages
Lithuanian (lt)
Other versions
LT5855B (en
Inventor
Milda PLEČKAITYTĖ
Edita MIŠTINIENĖ
Jonas Henrikas Pesliakas
Gintautas ŽVIRBLIS
Aurelija ŽVIRBLIENĖ
Original Assignee
Uab Profarma, ,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Profarma, , filed Critical Uab Profarma, ,
Priority to LT2010104A priority Critical patent/LT5855B/en
Priority to EP11718794A priority patent/EP2563810A1/en
Priority to PCT/LT2011/000004 priority patent/WO2012078014A1/en
Publication of LT2010104A publication Critical patent/LT2010104A/en
Publication of LT5855B publication Critical patent/LT5855B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Recombinant antibody fragment scFv was obtained from hybridoma 9B4 (DSM ACC2991) by genetic engineering method. It was purified successfully and its specific activity towards VLY cytolysin from G. vaginalis was disclosed, as well as effective neutralization of cytolytic activity. As demonstrated by the invention the recombinant antibody fragment scFv may be used for therapy and prevention of pathology caused by G. vaginalis. Single stranded antibody fragments thus obtained reveals important advantages against traditionally obtained monoclonal antibodies: they may be prepared by simpler and cheaper process of bacterial biosynthesis; due to smaller molecular weight such proteins penetrates easier into tissues affected by infection.@
LT2010104A 2010-12-07 2010-12-07 Single stranded recombinant antibody fragment able to neutralize cytolytic activity of vaginolysin LT5855B (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
LT2010104A LT5855B (en) 2010-12-07 2010-12-07 Single stranded recombinant antibody fragment able to neutralize cytolytic activity of vaginolysin
EP11718794A EP2563810A1 (en) 2010-12-07 2011-03-28 Recombinant single-chain antibody fragment neutralizing the cytolytic activity of vaginolysin
PCT/LT2011/000004 WO2012078014A1 (en) 2010-12-07 2011-03-28 Recombinant single-chain antibody fragment neutralizing the cytolytic activity of vaginolysin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LT2010104A LT5855B (en) 2010-12-07 2010-12-07 Single stranded recombinant antibody fragment able to neutralize cytolytic activity of vaginolysin

Publications (2)

Publication Number Publication Date
LT2010104A true LT2010104A (en) 2012-06-25
LT5855B LT5855B (en) 2012-08-27

Family

ID=44227537

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2010104A LT5855B (en) 2010-12-07 2010-12-07 Single stranded recombinant antibody fragment able to neutralize cytolytic activity of vaginolysin

Country Status (3)

Country Link
EP (1) EP2563810A1 (en)
LT (1) LT5855B (en)
WO (1) WO2012078014A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015003114A1 (en) * 2013-07-05 2015-01-08 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
CN104173985A (en) * 2014-09-02 2014-12-03 郭书堂 Medicine for treating female postpartum cold and preparation method of medicine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802112B2 (en) * 2008-03-15 2014-08-12 The Trustees Of Columbia University In The City Of New York Treatment and prevention of Gardnerella vaginalis infections
LT5705B (en) 2009-02-23 2011-01-25 Uab Profarma Monoclonal antibodies against vaginolysin

Also Published As

Publication number Publication date
LT5855B (en) 2012-08-27
EP2563810A1 (en) 2013-03-06
WO2012078014A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
MX2020009366A (en) Anti-cd73 antibodies and uses thereof.
TW201613970A (en) Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CR20200567A (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
MY157109A (en) Antibodies to human gdf8
PH12015501593A1 (en) Stable and soluble antibodies inhibiting vegf
GEP20217260B (en) Antibody neutralizing human respiratory syncytial virus
MX2011012039A (en) Blocking anti-dkk-1 antibodies and their uses.
UA116873C2 (en) Antibodies that bing to ox40 and their uses
MX2012010793A (en) Compositions and methods for the removal of biofilms.
WO2012045001A3 (en) Influenza virus antibodies and immunogens and uses therefor
AU2012249274A8 (en) Neutralizing antibodies to Nipah and Hendra virus
UA99633C2 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
GB201003701D0 (en) System for the expression of a protein
WO2011004028A3 (en) Tlr3 binding agents
WO2021212049A3 (en) Anti-sars-cov-2 monoclonal antibodies
MX2013000958A (en) Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma.
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
WO2012009631A8 (en) Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
WO2018194496A3 (en) Monoclonal antibody to pd-l1
WO2010092176A3 (en) Nontypable haemophilus influenzae antigens
MX2022012628A (en) Anti-phf-tau antibodies and uses thereof.
MX2017015690A (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor.
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
MX2021012769A (en) Cd73 blocking antibodies.